

Inosi Therapeutics announces TTRA funding with support from IP Group and BioCurate

Melbourne, Australia: June 20th, 2025

Inosi Therapeutics has been awarded \$968,192 grant funding from the Targeted Translation Research Accelerator (TTRA) to progress its development program into IND enabling studies for “Development of an IRAP inhibitor for the treatment of Diabetic Kidney Disease”.

Inosi Therapeutics’ lead program is focused on developing therapies to treat chronic disease conditions due to fibrosis (scarring). These fibrotic diseases include chronic kidney disease and cardiovascular disease, with high unmet patient need. These treatments could change lives, keeping patients off dialysis and lowering the risk of heart failure.

Filippa Shub, COO of Inosi Therapeutics commented that “the TTRA Diabetes and Cardiovascular Disease program delivered by MTPConnect as part of the Medical Research Futures Fund, is designed with translation and commercialization at the forefront, and is a fantastic fit for the Inosi drug development program. We look forward to working closely with the TTRA team to accelerate progress to the clinic.”

The company has also received an additional \$2 million funding from IP Group and BioCurate to match the grant and more broadly drive the company’s anti-fibrotic program forward.

“BioCurate is delighted to be investing alongside IP Group, to leverage the TTRA funding. We are excited to be supporting Inosi Therapeutics’ novel therapeutic approach to serious chronic disease. This treatment could be a game changer for millions of people living with kidney disease with the potential to prevent the need for dialysis and kidney transplantation” said Dr Kathy Nielsen, CEO of BioCurate.

Dr Siro Perez, Partner & Head of Life Sciences, APAC, IP Group Australia, said “Inosi Therapeutics is a great example of the pioneering research that IP Group is backing. We’re delighted to have made this ongoing investment in Inosi to develop these important therapies for serious chronic disease and grow the company to its next key milestone.”

Inosi’s technology is based on research licensed from Monash University. The program originated from a collaboration with University of Melbourne affiliates, St Vincent’s Institute of Medical Research and the Florey Institute of Neuroscience and Mental Health.

About TTRA

Since 2020, MTPConnect has delivered the inaugural \$47 million TTRA program for diabetes and cardiovascular disease on behalf of the MRFF. In July 2024, MTPConnect was selected to deliver the MRFF Preventive and Public Health Research Initiative 2023 TTRA – Cardiovascular Disease and Diabetes Drugs and Devices grant opportunity (TTRA Drugs and Devices), building on the legacy of the inaugural TTRA program. The objective of TTRA Drugs and Devices is to improve the health and wellbeing of Australians by accelerating into practice promising drugs

and medical devices that reduce the burden of cardiovascular disease and complications of diabetes for patients, carers, families and community.

MTPConnect is Australia's Life Sciences Innovation Accelerator – an independent, not-for-profit organisation established by the Australian Government to champion the continuing growth of Australia's vibrant medical products sector.

About IP Group

IP Group develops world-changing science and technology businesses across life sciences, technology and cleantech. The Group has a strong track record of success, having been the founder investor in several high-profile companies including Oxford Nanopore Technologies plc. In Australia and New Zealand, IP Group works in close partnership with the Go8 Universities and the University of Auckland to identify ground-breaking technologies rooted in hard science, which have the most promising commercial potential. IP Group is listed on the Main Market of the London Stock Exchange under the code IPO.

For more information www.ipgroupanz.com

About BioCurate

BioCurate's mission is to identify promising biomedical research discoveries and manages their translation into high-quality pre-clinical candidates for novel human therapeutics. BioCurate was formed jointly by The University of Melbourne and Monash University, with support from the Victorian State. BioCurate is operationally independent, with a team of experts who bring decades of scientific and commercial expertise, and an extensive global network, enabling BioCurate to recognise and realise real-world potential and provides a critical bridge between academia and industry within the biotechnology sector to accelerate the development of new therapies.

For more information, please visit <http://www.biocurate.com>